Contact Information: CONTACT: James E. Fickenscher Chief Financial Officer Auxilium Pharmaceuticals, Inc. +1-484-321-5900 or William Q. Sargent Jr. Vice-President, Investor Relations and Corporate Communications +1-484-321-5900
Auxilium Pharmaceuticals, Inc. Announces Pricing of a Public Offering of Common Stock
| Source: Auxilium Pharmaceuticals, Inc.
MALVERN, PA--(Marketwire - September 25, 2009) - Auxilium Pharmaceuticals, Inc. (NASDAQ : AUXL ),
a specialty biopharmaceutical company, today announced the pricing of a
public offering of 3 million shares of its common stock. The offering is
expected to close on or about September 30, 2009, subject to customary
closing conditions. In addition, Auxilium has granted the underwriter a
30-day option to purchase up to an additional 450,000 shares to cover
over-allotments, if any.
Jefferies & Company is acting as sole book-running manager in this
offering.
A registration statement relating to the shares of common stock issued in
the offering has been filed with, and declared effective by, the Securities
and Exchange Commission (the "SEC"). This offering is being made pursuant
to a prospectus supplement to the registration statement. Copies of the
final prospectus supplement and related prospectus, when available, may be
obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus
Department, 520 Madison Avenue, New York, NY 10022 or at (888) 449-2342.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or jurisdiction.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the expected closing date of the announced public offering and
the filing of a final prospectus supplement with the SEC (including
statements of assumption underlying or relating to any of the foregoing).
Actual results may differ materially from those reflected in these
forward-looking statements due to various factors, including risks related
to the underwriter's consummation of its obligations to purchase the
securities, whether Auxilium will be able to satisfy its conditions to
close the offering, further evaluation of clinical data, results of
clinical trials, decisions by regulatory authorities as to whether and when
to approve drug applications, general financial, economic, regulatory and
political conditions affecting the biotechnology and pharmaceutical
industries, those risks discussed in Auxilium's Annual Report on Form 10-K
for the year ended December 31, 2008 and in Auxilium's Quarterly Report on
Form 10-Q for the period ended June 30, 2009 under the heading "Risk
Factors," which are on file with the SEC and may be accessed electronically
by means of the SEC's home page on the Internet at http://www.sec.gov and
other additional risks that Auxilium does not presently know or that
Auxilium currently believes are immaterial. Given these risks and
uncertainties, any or all of these forward-looking statements may prove to
be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. While Auxilium may elect to update these
forward-looking statements at some point in the future, Auxilium
specifically disclaims any obligation to do so.